Introduction
Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by low platelet counts and an increased risk of bleeding. Based on best estimates, the ageadjusted prevalence of ITP in the US is estimated at about 9.5/100,000 persons, 1 with an annual incidence of 3.3 per 100,000 adults, 2 or ~3,900-9,500 new cases diagnosed in the US each year. 3 A recent study based on US administrative claims data found a median age at diagnosis of 53 years. eltrombopag (EPAG) and romiplostim (ROMI), accomplish this by stimulating platelet production. 5 In the US, both are indicated for the treatment of cITP in adults who have had inadequate response to other therapies, including corticosteroids, immunoglobulins, and splenectomy. 6 Several studies have assessed the cost per responder of ROMI, [7] [8] [9] [10] although they did not compare these costs to EPAG and were not in a US setting. To date, there have been no headto-head clinical trials comparing EPAG and ROMI, and few indirect treatment comparisons (ITCs) have been developed to assess the efficacy and safety of these therapies (eg, Allen et al 11 ).
It is important to understand the cost consequences of utilizing different second-line options for the treatment of cITP. One study 12 has described a cost per response analysis comparing EPAG to ROMI and "watch and rescue" (W&R) and found TPO-RAs to be efficient in achieving treatment success with lower costs per treatment success.
However, additional studies are required to better understand current utilization, effectiveness of treatment modalities, and the impact of clinical outcomes on cITP.
Here, we present the results of a cost-consequence model that compared EPAG to ROMI and W&R among previously treated adult patients in the US.
Materials and methods
Model perspective, patient populations, and horizon/discounting A general US payer's perspective and a time horizon of 26 weeks were used. The population consisted of adult patients with cITP who had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. As splenectomy status is a key prognostic factor in ITP, 13, 14 cost-consequence results for splenectomized and non-splenectomized patients were also reported separately. The trial data cutoff (26 weeks) was used for the time horizon, as certain endpoints used in the model are bound to within-trial results. This also allows the use of direct evidence from the published literature without relying on extrapolation techniques that require additional assumptions. Discounting was not applied, as the model horizon was <1 year. An overview is presented in Figure 1 .
Comparators
After performing a targeted literature review, EPAG and ROMI, along with W&R (placebo), were determined to be included as comparators. The respective trials' placebo groups constituted W&R, as these patients only received rescue therapy as needed. Rituximab and splenectomy, while common treatment options for ITP, were not included as comparators due to significant noncomparability between the trial populations.
Efficacy and dosing data were derived from one clinical trial for EPAG (Cheng et al 5 ) and one trial for ROMI (Kuter et al 18 ).
We performed an ITC that assessed severe bleeding events as the primary endpoint. Severe bleeding (WHO grade 3-5) was chosen as the primary endpoint for three main reasons: 1) complete data on severe bleeding were reported for both clinical trials; 2) bleeding, unlike endpoints such as platelet 19 for ROMI) had similar baseline characteristics. The most notable differences at baseline were in the proportion of splenectomized patients (36% in the EPAG trial vs 50% in the ROMI trial), the proportion of patients who had received three or more prior ITP medications (54% in the EPAG trial vs 63% in the ROMI trial), and the proportion of patients receiving concomitant medications (48% in the EPAG trial vs 31% in the ROMI trial).
The designs of the two trials were deemed acceptably comparable, but several differences were noted: the EPAG trial did not allow tapering of concomitant ITP medication during the first 6 weeks of treatment, while the ROMI trial allowed dose reduction or discontinuation of ITP medications during the first 12 weeks of treatment, which may have impacted platelet response. The definitions of platelet response differed slightly between the two studies: in Cheng et al, 5 platelet counts >400,000/µL were not considered a response, while they were in Kuter et al. 19 Rescue treatment duration assumptions varied between the two studies, as Cheng et al 5 assumed that rescue treatment continued until platelet counts returned to normal levels and Kuter et al 19 assumed that rescued treatment continued for a fixed period of 8 weeks. Overall, the two trials were considered comparable enough to satisfy the transitivity assumption.
Using ITC, ROMI efficacy data were adjusted to match the EPAG trial. Therefore, EPAG and W&R (no drug treatment) efficacy data were taken directly from the trial, 20 while the ROMI data (from Kuter et al 19 ) were adjusted. Frequentist ITC was used, and 95% confidence intervals were calculated. ROMI results were pooled using random-effects models (Mantel-Haenszel method), which generated ORs for ROMI vs placebo. Classical frequentist ITC was implemented using the Bucher (1997) method and 95% CIs. 21 
Patient flow
Patient flow in the model was based on epidemiology estimates for the US population, presented in Table 1 . Annual population growth rate for patient flow was assumed to be 0.79%. 22 
Efficacy measures
A summary of the efficacy values and the resulting odds ratios for treatment vs EPAG in all patients, as well as spenectomized and non-splenectomized patient groups, from the respective clinical trials, is presented in Table S1 . As was mentioned, these raw values were not used in the model and were instead matched through ITC by adjusting the ROMI efficacy data to match the placebo (W&R) group in the EPAG trial. Therefore, W&R results and EPAG results used in the model are identical to those of the EPAG trial, while the efficacy results for ROMI are adjusted. The primary efficacy measure was severe bleeding (WHO grades 3-5). The WHO bleeding scale used in the trials (ranging from 1 to 5) is the most commonly applied criteria in thrombocytopenia and was considered as a valid measure. 24 While platelet response is a commonly used primary endpoint in ITP, it was not assessed in this analysis. It should be noted that the correlation between platelet response and bleeding events has not been well characterized and may not be a perfect association. 15 While platelet count defines the diagnosis and is used to evaluate response to therapy in ITP, management decisions are driven by the prevention or treatment of bleeding. Therefore, bleeding is ultimately the most important endpoint to both patients and decision makers 15 and submit your manuscript | www.dovepress.com
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Severe bleeding was explored further by calculating the cost-effectiveness per severe bleeding event avoided (presented in the "Results" section).
Costs
Total costs associated with each treatment were based on the sum of drug costs, bleeding-related costs, routine care, drug administration, rescue medications, adverse events (all grades presenting in >20% of patients in at least one of the included trials), and mortality costs. The proportion of patients requiring these resources in each treatment arm was derived from the respective clinical trials, 18, 25 if available, or from other published literature (Table 2 ). In addition to the ITT population, splenectomized and non-splenectomized subgroups were assessed.
To account for the fact that the available pack sizes of drugs may not allow for the exact dose of drug required, wastage was applied for dose calculations based on the received doses (ie, doses were rounded up to the nearest pack/vial size when necessary). Wastage and dose reductions were only included for the primary therapies (EPAG and ROMI). A breakdown of the cost calculations are presented in Tables  S2-S4 . Included costs were summed to obtain the total cost associated with each primary therapy. Resources used in the analysis and their sources are summarized in Table 2 .
Probabilistic sensitivity analyses (Psas)
Uncertainty in the results was assessed with PSAs, where probabilistic distributions were directly applied to the base case model for the ITT, splenectomized, and non-splenectomized populations. All efficacy and cost parameters were explored in the PSA and are presented in the "Results" section.
Results
The summed overall costs and efficacy results for each primary therapy are shown in Table 3 . Specific costs and the raw efficacy data from the clinical trials are presented in Tables S3-S10. As was mentioned, efficacy data from the ITC were used in the model, where the ROMI efficacy data was adjusted to match the placebo (W&R) group to the EPAG trial. Therefore, W&R results and EPAG results used in the model are identical to those of the EPAG trial, while the 
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efficacy results for ROMI are adjusted (as described earlier). After ITC, severe bleeding rates in ROMI-treated patients decreased to 3.7% from the 7.1% reported in the trial, as the placebo group in the Kuter et al 19 study experienced a higher severe bleeding rate than that in the EPAG trial. 5 In the ITT populations, EPAG, ROMI, and W&R had total estimated costs of US$66,560, US$91,039, and US$30,099, respectively. In this population, EPAG was estimated to cost US$24,480 (26.9%) less than ROMI. Compared with W&R, EPAG costs US$36,460 (121.1%) more, while ROMI costs US$60,940 (202.5%) more.
In the splenectomized population, EPAG was estimated to cost US$25,487 (27.9%) less than ROMI. Compared with W&R, EPAG cost US$34,436 (109.1%) more, while Drug costs comprised the vast majority of the price for all comparators.
In the analysis of severe bleeding, EPAG showed a 1.5% incremental benefit (1.66-fold improvement) over ROMI and a 4.2% benefit (2.90-fold improvement) over W&R in the ITT population, while ROMI showed an incremental benefit of 2.8% (1.75-fold improvement) over W&R. In splenectomized patients, these differences were exaggerated, with EPAG showing a 3.5% incremental benefit (4.50-fold improvement) over ROMI and an 8.5% benefit (9.52-fold improvement) over W&R and ROMI showing an incremental benefit of 5.0% (2.12-fold improvement) over W&R. In non-splenectomized patients, the differences were tempered, as EPAG showed a 1.1% incremental benefit (1.32-fold improvement) over ROMI and a 1.3% benefit (1.38-fold improvement) over W&R. ROMI showed an incremental benefit of 0.2% (1.05-fold improvement) over W&R when assessing severe bleeding in non-splenectomized patients. Incremental cost-effectiveness ratios (ICERs ; Table 4 ) were derived to further explore cost per severe bleeding event. When assessing cost per severe bleeding avoided in the ITT population, EPAG dominated ROMI and had an ICER of US$862,071 when compared to W&R, while ROMI had an ICER of US$2,197,935 compared to W&R. In splenectomized patients, EPAG again dominated ROMI and had a reduced ICER of US$403,994 when compared with W&R, while ROMI had a reduced ICER of US$1,192,142 compared with W&R. With regard to non-splenectomized patients, EPAG again dominated ROMI, with an increased ICER of US$2,802,913 when compared with W&R, while ROMI had a more greatly increased ICER of US$26,696,956 compared with W&R.
sensitivity analyses
Uncertainty in the cost-effectiveness results for severe bleeding events avoided was assessed with PSAs. Deterministic sensitivity analyses were also intended to assess incremental cost-effectiveness for severe bleeding. However, these analyses were not feasible because EPAG was dominant over ROM I for severe bleeding and therefore the relevant base case ICER was unavailable. For the PSA, probabilistic distributions were directly applied to the base case model for the ITT population. The parameters explored in the PSA are presented in Table 5 . Point estimates and standard errors (SEs) were from the respective clinical trials.
PSA results were relatively consistent with the base case findings, where the majority of iterations were located in the southwest quadrant showing greater EPAG efficacy, with a lower EPAG cost (Figure 2 ).
Discussion
The previous cost-consequence model comparing EPAG to ROMI 12 found that costs per responder for EPAG, ROMI, and W&R were US$64,314, US$58,990, and US$118,314, respectively. However, key limitations in this analysis were identified.
In the analysis by Li et al, 12 epidemiology estimates for patient flow were not presented. Additionally, there was no formal comparison of trial, population, or settings to determine if proper comparators were used. Instead, naïve analyses were used to compare the trial data, and no assessment was made to ensure the trials were comparable. When a deviation from the transitivity assumption exists, a model based on an ITC is more likely to validly compare clinical trial data. 34 Further limiting the Li et al 12 analysis, adverse event and mortality costs were not included, and the only endpoint included was cost per responder based on platelet count (which is a problematic endpoint when determining any sort of clinical or economic benefit, as response is not necessarily associated with tangible implications). Additionally, wastage analysis was not presented. Finally, no sensitivity analyses were performed to explore the uncertainty of their results. These gaps were all addressed in the present study.
In our model, following ITC adjustment, the rate of severe bleeding in EPAG was 2.2% compared to 3.7% with ROMI, which accounted for the difference in bleeding-related costs. In the ITT population, EPAG, ROMI, and W&R had total estimated costs of US$66,560, US$91,039, and US$30,099, respectively, with drug costs comprising most of the price for all comparators. The lower total cost of EPAG and higher severe bleeding events avoided led EPAG to dominate ROMI. When compared to W&R in our assessment, EPAG had a higher total cost and a resulting ICER of US$862,071 per severe bleeding event avoided. When assessing subgroups in our analysis, EPAG generally showed the most favorable results in the splenectomized population subgroup, dominating ROMI for severe bleeding event avoided. PSA results were relatively consistent with the base case findings.
Our study had several limitations. Because of inconsistent reporting in the literature, endpoint definitions in the trials varied occasionally, making direct matching and data selection challenging. Rituximab and splenectomy, two common treatments for cITP, could not be included as comparators due to differences in patient characteristics and study design. 16 The time horizon used in this model was relatively short but allowed modeling of within-trial endpoints without the need for extrapolation techniques. Lastly, since there is currently no established cost-effectiveness threshold for severe bleeding events avoided, the interpretation of the ICER results presented can be challenging.
To our knowledge, this is the most comprehensive costconsequence model comparing EPAG with ROMI in adults with cITP who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. This is an area of interest to physicians and health care decision-makers who are seeking to determine the best available treatment options for these patients. The results of our analysis indicate that EPAG is cost-effective for the treatment of cITP when assessing cost per severe bleeding event avoided. Additional analyses are planned to investigate cost comparisons between EPAG and ROMI in pediatric patients.
Conclusion
Overall, EPAG was dominant (less expensive with fewer severe bleeding events) compared with ROMI and had notably fewer severe bleeding events compared with W&R. Further evaluations that incorporate long-term extrapolation and preference-based outcomes (quality-adjusted life year and life year) would be meaningful additions to the evidence base for treatment of cITP. 
